Improving outcomes in patients with oesophageal cancer.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
accepted:
24
03
2023
medline:
25
5
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
The care of patients with oesophageal cancer or of individuals who have an elevated risk of oesophageal cancer has changed dramatically. The epidemiology of squamous cell and adenocarcinoma of the oesophagus has diverged over the past several decades, with a marked increase in incidence only for oesophageal adenocarcinoma. Only in the past decade, however, have molecular features that distinguish these two forms of the disease been identified. This advance has the potential to improve screening for oesophageal cancers through the development of novel minimally invasive diagnostic technologies predicated on cancer-specific genomic or epigenetic alterations. Surgical techniques have also evolved towards less invasive approaches associated with less morbidity, without compromising oncological outcomes. With improvements in multidisciplinary care, advances in radiotherapy and new tools to detect minimal residual disease, certain patients may no longer even require surgical tumour resection. However, perhaps the most anticipated advance in the treatment of patients with oesophageal cancer is the advent of immune-checkpoint inhibitors, which harness and enhance the host immune response against cancer. In this Review, we discuss all these advances in the management of oesophageal cancer, representing only the beginning of a transformation in our quest to improve patient outcomes.
Identifiants
pubmed: 37085570
doi: 10.1038/s41571-023-00757-y
pii: 10.1038/s41571-023-00757-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-407Informations de copyright
© 2023. Springer Nature Limited.
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer Statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
pubmed: 36633525
doi: 10.3322/caac.21763
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
pubmed: 33433946
doi: 10.3322/caac.21654
He, H. et al. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thorac. Cancer 11, 1121–1128 (2020).
pubmed: 32154652
doi: 10.1111/1759-7714.13311
pmcid: 7180574
Njei, B., McCarty, T. R. & Birk, J. W. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J. Gastroenterol. Hepatol. 31, 1141–1146 (2016).
pubmed: 26749521
doi: 10.1111/jgh.13289
pmcid: 4885788
Arnold, M., Soerjomataram, I., Henegouwen, M. B. & Soerjomataram, I. Global incidence of oesophageal cancer and gastric cancer by histology and subsite in 2018. Gut 69, 1564–1571 (2020).
pubmed: 32606208
doi: 10.1136/gutjnl-2020-321600
Abnet, C. C., Arnold, M. & Wei, W. Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018).
pubmed: 28823862
doi: 10.1053/j.gastro.2017.08.023
Zang, Z. et al. Dietary patterns and severity of symptom with the risk of esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional latent class analysis. BMC Cancer 22, 95 (2022).
pubmed: 35062901
doi: 10.1186/s12885-022-09206-y
pmcid: 8783423
McCormack, V. A. et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting-specific exposures to known and putative risk factors. Int. J. Cancer 140, 259–271 (2017).
pubmed: 27466161
doi: 10.1002/ijc.30292
Lin, Y. et al. Esophageal cancer in high-risk areas of China: research progress and challenges. Ann. Epidemiol. 27, 215–222 (2017).
pubmed: 28007352
doi: 10.1016/j.annepidem.2016.11.004
Arnal, M. J. D., Arenas, A. F. & Arbeloa, A. L. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J. Gastroenterol. 21, 7933–7943 (2015).
doi: 10.3748/wjg.v21.i26.7933
Shah, M. A. et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J. Clin. Oncol. 38, 2677–2694 (2020).
pubmed: 32568633
doi: 10.1200/JCO.20.00866
Kojima, T. et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138–4148 (2020).
pubmed: 33026938
doi: 10.1200/JCO.20.01888
Shah, M. A. et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastateic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 5, 546–550 (2019).
pubmed: 30570649
doi: 10.1001/jamaoncol.2018.5441
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastroesophageal junction, and oesophageal adenocarcioma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
pubmed: 34102137
doi: 10.1016/S0140-6736(21)00797-2
pmcid: 8436782
Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942–948 (2022).
pubmed: 35322232
doi: 10.1038/s41586-022-04508-4
pmcid: 8967713
Sun, J. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759–771 (2021).
pubmed: 34454674
doi: 10.1016/S0140-6736(21)01234-4
Doki, Y., Ajani, J. A., Kato, K. & Xu, J. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449–462 (2022).
pubmed: 35108470
doi: 10.1056/NEJMoa2111380
Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191–1203 (2021).
pubmed: 33789008
doi: 10.1056/NEJMoa2032125
Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade for HER2-positive gastric cancer. Nature 600, 727–730 (2021).
pubmed: 34912120
doi: 10.1038/s41586-021-04161-3
pmcid: 8959470
Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419–2430 (2020).
pubmed: 32469182
doi: 10.1056/NEJMoa2004413
Shah, M. A. et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J. Clin. Oncol. 41, 1470–1491 (2023).
pubmed: 36603169
doi: 10.1200/JCO.22.02331
The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
doi: 10.1038/nature20805
pmcid: 5651175
Campbell, J. D. et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 23, 194–212 (2018).
pubmed: 29617660
doi: 10.1016/j.celrep.2018.03.063
pmcid: 6002769
Quante, M., Wang, T. C. & Bass, A. J. Adenocarcinoma of the oesophagus: is it gastric cancer? Gut https://doi.org/10.1136/gutjnl-2022-327096 (2022).
doi: 10.1136/gutjnl-2022-327096
pubmed: 35365571
Dotto, G. P. & Rustgi, A. K. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell 29, 622–637 (2016).
pubmed: 27165741
doi: 10.1016/j.ccell.2016.04.004
pmcid: 4870309
Yokoyama, T. et al. Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol. Biomarkers Prev. 12, 1227–1233 (2003).
pubmed: 14652286
Wang, G. Q. et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 54, 187–192 (2005).
pubmed: 15647178
doi: 10.1136/gut.2004.046631
pmcid: 1774842
Liu, X. et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology 153, 166–177 (2017).
pubmed: 28365443
doi: 10.1053/j.gastro.2017.03.033
Liao, G. et al. Single-cell transcriptomics provides insights into the origin and microenvironment of human oesophageal high-grade intraepithelial neoplasia. Clin. Transl. Med. 12, e874 (2022).
pubmed: 35608199
doi: 10.1002/ctm2.874
pmcid: 9128161
Que, J., Garman, K. S., Souza, R. F. & Spechler, S. J. Pathogenesis and cells of origin of Barrett’s esophagus. Gastroenterology 157, 349–364.e1 (2019).
pubmed: 31082367
doi: 10.1053/j.gastro.2019.03.072
Nowicki-Osuch, K. et al. Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition. Science 373, 760–767 (2021).
pubmed: 34385390
doi: 10.1126/science.abd1449
Sawas, T. et al. Magnitude and time-trend analysis of postendoscopy esophageal adenocarcinoma: a systemic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, e31–e50 (2022).
pubmed: 33901662
doi: 10.1016/j.cgh.2021.04.032
Sawas, T. et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology 155, 1720–1728 (2018).
pubmed: 30165050
doi: 10.1053/j.gastro.2018.08.036
Stachler, M. D. et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology 155, 156–167 (2018).
pubmed: 29608884
doi: 10.1053/j.gastro.2018.03.047
Killcoyne, S. et al. Genomic copy number predicts esophageal cancer years before transformation. Nat. Med. 26, 1726–1732 (2020).
pubmed: 32895572
doi: 10.1038/s41591-020-1033-y
pmcid: 7116403
Fitzgerald, R. C. et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicenter, pragmatic, randomised controlled trial. Lancet 396, 333–344 (2020).
pubmed: 32738955
doi: 10.1016/S0140-6736(20)31099-0
pmcid: 7408501
Wu, W. et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology 144, 956–966 (2013).
pubmed: 23333711
doi: 10.1053/j.gastro.2013.01.019
Jammula, S. et al. Identification of subtypes of Barrett’s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptome and genome data. Gastroenterology 158, 1682–1697 (2020).
pubmed: 32032585
doi: 10.1053/j.gastro.2020.01.044
Stachler, M. D. et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat. Genet. 47, 1047–1055 (2015).
pubmed: 26192918
doi: 10.1038/ng.3343
pmcid: 4552571
Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49–58 (2018).
pubmed: 29122777
doi: 10.1158/2159-8290.CD-17-0787
Wong, G. S. et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat. Med. 24, 968–977 (2018).
pubmed: 29808010
doi: 10.1038/s41591-018-0022-x
pmcid: 6039276
Kim, J. et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J. Clin. Investig. 124, 5145–5158 (2014).
pubmed: 25401468
doi: 10.1172/JCI75200
pmcid: 4348950
Salem, M. E. et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist 23, 1319–1327 (2018).
pubmed: 29866946
doi: 10.1634/theoncologist.2018-0143
pmcid: 6291329
Colom, B. et al. Mutant clones in normal epithelium outcompete and eliminate emerging tumours. Nature 598, 510–514 (2021).
pubmed: 34646013
doi: 10.1038/s41586-021-03965-7
pmcid: 7612642
Brown, J., Stepien, A. J. & Willem, P. Landscape of copy number aberrations in esophageal squamous cell carcinoma from a high endemic region of South Africa. BMC Cancer 20, 281 (2020).
pubmed: 32252688
doi: 10.1186/s12885-020-06788-3
pmcid: 7137242
Zhou, J. et al. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. Gut 71, 665–675 (2022).
pubmed: 33789967
doi: 10.1136/gutjnl-2020-323276
Baba, Y. et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 111, 3132–3141 (2020).
pubmed: 32579769
doi: 10.1111/cas.14541
pmcid: 7469863
Okadome, K. et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. Br. J. Cancer 122, 1535–1543 (2020).
pubmed: 32210369
doi: 10.1038/s41416-020-0811-0
pmcid: 7217865
Karakasheva, T. A. et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res. 75, 4074–4085 (2015).
pubmed: 26294209
doi: 10.1158/0008-5472.CAN-14-3639
pmcid: 4592477
Shaheen, N. J. et al. Diagnosis and management of Barrett’s esophagus: an updated ACG guideline. Am. J. Gastroenterol. 117, 559–587 (2022).
pubmed: 35354777
doi: 10.14309/ajg.0000000000001680
American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 140, 1084–1091 (2011).
doi: 10.1053/j.gastro.2011.01.030
Verbeek, R. E. et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am. J. Gastroenterol. 109, 1215–1222 (2014).
pubmed: 24980881
doi: 10.1038/ajg.2014.156
Tramontano, A. C. et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am. J. Gastroenterol. 112, 1256–1264 (2017).
pubmed: 28374815
doi: 10.1038/ajg.2017.82
pmcid: 5856156
Moinova, H. R. et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci. Transl. Med. 10, eaao5848 (2018).
pubmed: 29343623
doi: 10.1126/scitranslmed.aao5848
pmcid: 5789768
Iyer, P. G. et al. Accurate nonendoscopic detection of Barrett’s esophagus by methylated DNA markers: a multisite case control study. Am. J. Gastroenterol. 115, 1201–1209 (2020).
pubmed: 32558685
doi: 10.14309/ajg.0000000000000656
pmcid: 7415629
Bhat, S. et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut 64, 20–25 (2015).
pubmed: 24700439
doi: 10.1136/gutjnl-2013-305506
El-Serag, H. B. et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut 65, 1252–1260 (2016).
pubmed: 26311716
doi: 10.1136/gutjnl-2014-308865
Corley, D. A. et al. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology 145, 312–319 (2013).
pubmed: 23673354
doi: 10.1053/j.gastro.2013.05.004
Abrams, J. A. et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 7, 736–742 (2009).
pubmed: 19268726
doi: 10.1016/j.cgh.2008.12.027
pmcid: 3139243
Runge, T. M., Abrams, J. A. & Shaheen, N. J. Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North. Am. 44, 203–231 (2015).
pubmed: 26021191
doi: 10.1016/j.gtc.2015.02.001
pmcid: 4449458
Hvid-Jensen, F. et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N. Engl. J. Med. 365, 1375–1383 (2011).
pubmed: 21995385
doi: 10.1056/NEJMoa1103042
Kastelein, F. et al. Aberrant p53 protein expression is associated with increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut 62, 1676–1683 (2013).
pubmed: 23256952
doi: 10.1136/gutjnl-2012-303594
Redston, M. et al. Abnormal TP53 predicts risk of progression in patients with Barrett’s esophagus regardless of a diagnosis of dysplasia. Gastroenterology 162, 468–481 (2022).
pubmed: 34757142
doi: 10.1053/j.gastro.2021.10.038
Peters, Y., van Grinsven, E. & Siersema, P. D. Systematic review with meta-analysis: the effects of family history on the risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 54, 868–879 (2021).
pubmed: 34383966
doi: 10.1111/apt.16558
pmcid: 9292032
Glamour, B. K. et al. Age of diagnosis in familial Barrett’s associated neoplasia. Fam. Cancer 21, 115–120 (2022).
pubmed: 33694069
doi: 10.1007/s10689-021-00239-z
Fecteau, R. E. et al. Association between germline mutation in VSIG10L and familial Barrett neoplasia. JAMA Oncol. 2, 1333–1339 (2016).
pubmed: 27467440
doi: 10.1001/jamaoncol.2016.2054
pmcid: 5063702
Orloff, M. et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 306, 410–419 (2011).
pubmed: 21791690
doi: 10.1001/jama.2011.1029
pmcid: 3574553
Banerjee, B. et al. Clinical study of ursodeoxycholic acid in Barrett’s esophagus patients. Cancer Prev. Res. 9, 528–533 (2016).
doi: 10.1158/1940-6207.CAPR-15-0276
Chak, A. et al. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett’s esophagus. Clin. Gastroenterol. Hepatol. 13, 665–672 (2015).
pubmed: 25218668
doi: 10.1016/j.cgh.2014.08.040
Cummings, L. C. et al. A nonrandomized trial of vitamin D supplementation for Barrett’s esophagus. PLoS ONE 12, e0184928 (2017).
pubmed: 28922414
doi: 10.1371/journal.pone.0184928
pmcid: 5602627
Heath, E. I. et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J. Natl Canc. Inst. 99, 545–557 (2007).
doi: 10.1093/jnci/djk112
Joe, A. K. et al. Phase Ib randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in patients with Barrett’s esophagus. Cancer Prev. Res. 8, 1131–1137 (2015).
doi: 10.1158/1940-6207.CAPR-14-0274-T
Abrams, J. A. et al. Randomized controlled trial of the gastric/CCK2 receptor antagonist Netazepide in patients with Barrett’s esophagus. Cancer Prev. Res. 14, 675–682 (2021).
doi: 10.1158/1940-6207.CAPR-21-0050
Jankowski, J. A. Z. et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet 392, 400–408 (2018).
pubmed: 30057104
doi: 10.1016/S0140-6736(18)31388-6
pmcid: 6083438
National Health Commission of the People’s Republic of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). Chin. J. Cancer Res. 31, 223–258 (2019).
pubmed: 31156297
doi: 10.21147/j.issn.1000-9604.2019.02.01
pmcid: 6513746
Middleton, D. R. S. et al. Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. Int. J. Cancer 148, 1208–1218 (2021).
pubmed: 33128785
doi: 10.1002/ijc.33366
Roshandel, G. et al. Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. Br. J. Cancer 111, 2235–2241 (2014).
pubmed: 25247319
doi: 10.1038/bjc.2014.506
pmcid: 4264437
Gao, Y. et al. Feasibility and accuracy of artificial intelligence-assisted sponge cytology for community-based esophageal squamous cell carcinoma screening in China. Am. J. Gastroenterol. 116, 2207–2215 (2021).
pubmed: 34546186
doi: 10.14309/ajg.0000000000001499
Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
pubmed: 29348365
doi: 10.1126/science.aar3247
pmcid: 6080308
Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745–759 (2020).
pubmed: 33506766
doi: 10.1016/j.annonc.2020.02.011
Shaheen, N. J. et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med. 360, 2277–2288 (2009).
pubmed: 19474425
doi: 10.1056/NEJMoa0808145
Canto, M. I. et al. Multifocal cryoballoon ablation for eradication of Barrett’s esophagus-related neoplasia: a prospective multicenter clinical trial. Am. J. Gastroenterol. 115, 1879–1890 (2020).
pubmed: 33156107
doi: 10.14309/ajg.0000000000000822
Shaheen, N. J. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest. Endosc. 71, 680–685 (2010).
pubmed: 20363409
doi: 10.1016/j.gie.2010.01.018
pmcid: 3094022
Knabe, M. et al. Hybrid APC in combination with resection for the endoscopic treatment of neoplastic Barrett’s esophagus: a prospective, multicenter study. Am. J. Gastroenterol. 117, 110–119 (2022).
pubmed: 34845994
doi: 10.14309/ajg.0000000000001539
Ajani, J. A. et al. Esophageal and esophagogastric junction cancers. NCCN Guidelines Version 3.2022 1-162 (2019).
Pech, O. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146, 652–660 (2014).
pubmed: 24269290
doi: 10.1053/j.gastro.2013.11.006
Terheggen, G. et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett’s neoplasia. Gut 66, 783–793 (2017).
pubmed: 26801885
doi: 10.1136/gutjnl-2015-310126
Badreddine, R. J. et al. Depth of submucosal invasion does not predict lymph node metastases and survival of patients with esophageal carcinoma. Clin. Gastroenterol. Hepatol. 8, 248–253 (2010).
pubmed: 19948247
doi: 10.1016/j.cgh.2009.11.016
No Authors Listed. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest. Endosc. 58, S3–S43 (2003).
doi: 10.1016/S0016-5107(03)02159-X
Nieuwenhuis, E. A. et al. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma. Gastrointest. Endosc. 5107, 237–247.e3 (2022).
doi: 10.1016/j.gie.2022.03.005
Benech, N. et al. Endoscopic resection of Barrett’s adenocarcinoma: intramucosal and low-risk tumours are not associated with lymph node metastases. U. Eur. Gastroenterol. J. 9, 362–369 (2021).
doi: 10.1177/2050640620958903
Fotis, D. et al. Submucosal invasion and risk of lymph node invasion in early Barrett’s cancer: potential impact of different classification systems on patient management. U. Eur. Gastroenterol. J. 3, 505–513 (2015).
doi: 10.1177/2050640615581965
Guo, H. M., Zhang, X. Q., Chen, M., Huang, S. L. & Zou, X. P. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J. Gastroenterol. 20, 5540–5547 (2014).
pubmed: 24833885
doi: 10.3748/wjg.v20.i18.5540
pmcid: 4017070
Draganov, P. V., Wang, A. Y., Othman, M. O. & Fukami, N. AGA institute clinical practice update: endoscopic submucosal dissection in the United States. Clin. Gastroenterol. Hepatol. 17, 16–25 (2019).
pubmed: 30077787
doi: 10.1016/j.cgh.2018.07.041
Akutsu, Y. et al. The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer: from the results of JCOG0502, a prospective multicenter study. Ann. Surg. 264, 1009–1015 (2016).
pubmed: 27420375
doi: 10.1097/SLA.0000000000001557
Li, B. et al. Prevalence of lymph node metastases in superficial esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 146, 1198–1203 (2013).
pubmed: 23988285
doi: 10.1016/j.jtcvs.2013.07.006
Kato, K. et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology 161, 1878–1886 (2021).
pubmed: 34389340
doi: 10.1053/j.gastro.2021.08.007
Dimick, J. B., Wainess, R. M., Upchurch, G. R., Iannettoni, M. D. & Orringer, M. B. National trends in outcomes for esophageal resection. Ann. Thorac. Surg. 79, 212–216 (2005).
pubmed: 15620945
doi: 10.1016/j.athoracsur.2004.06.044
Mitzman, B., Schipper, P. H., Edwards, M. A., Kim, S. & Ferguson, M. K. Complications after esophagectomy are associated with extremes of body mass index. Ann. Thorac. Surg. 106, 973–980 (2018).
pubmed: 29936024
doi: 10.1016/j.athoracsur.2018.05.056
Kuppusamy, M. K. & Low, D. E., International Esodata Study Group (IESG). Evaluation of international contemporary operative outcomes and management trends associated with esophagectomy: a 4-year study of >6000 patients using ECCG definitions and the online Esodata database. Ann. Surg. 275, 515–525 (2022).
pubmed: 33074888
doi: 10.1097/SLA.0000000000004309
Voeten, D. M. et al. Outcomes of esophagogastric cancer surgery during eight years of surgical auditing by the Dutch Upper Gastrointestinal Cancer Audit (DUCA). Ann. Surg. 274, 866–873 (2021).
pubmed: 34334633
doi: 10.1097/SLA.0000000000005116
van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074–2084 (2012).
pubmed: 22646630
doi: 10.1056/NEJMoa1112088
Haverkamp, L., Seesing, M. F. J., Ruurda, J. P., Boone, J. & Hillegersberg, R. V. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis. Esophagus 30, 1–7 (2017).
pubmed: 27001442
Schlottman, F., Strassle, P. D. & Patti, M. G. Transhiatal vs transthoracic esophagectomy: a NSQIP analysis of postoperative outcomes and risk factors for morbidity. J. Gastrointest. Surg. 21, 1757–1763 (2017).
doi: 10.1007/s11605-017-3572-1
Hulscher, J. B. et al. Extending transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N. Engl. J. Med. 347, 1662–1669 (2002).
pubmed: 12444180
doi: 10.1056/NEJMoa022343
van Workum, F., Fransen, L., Dp Luyer, M. & Rosman, C. Learning curves in minimally invasive esophagectomy. World J. Gastroenterol. 24, 4974–4978 (2018).
pubmed: 30510372
doi: 10.3748/wjg.v24.i44.4974
pmcid: 6262255
Blears, E., Fernando, H. C., Shahoud, J. & Weksler, B. Factors associated with access and approach to esophagectomy for cancer: a National Cancer Database study. Surg. Endosc. 36, 7016–7024 (2022).
pubmed: 35059836
doi: 10.1007/s00464-022-09032-0
Straatman, J. et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME trial. Ann. Surg. 266, 232–236 (2017).
pubmed: 28187044
doi: 10.1097/SLA.0000000000002171
Biere, S. S. et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379, 1887–1892 (2012).
pubmed: 22552194
doi: 10.1016/S0140-6736(12)60516-9
Nuytens, F. et al. Five-year survival outcomes of hybrid minimally invasive esophagectomy in esophageal cancer: results of the MIRO randomized clinical trial. JAMA Surg. 156, 323–332 (2021).
pubmed: 33595631
doi: 10.1001/jamasurg.2020.7081
pmcid: 7890455
Yang, Y. et al. Robot-assisted versus conventional minimally invasive esophagectomy for resectable esophageal squamous cell carcinoma: early results of a multicenter randomized controlled trial: the RAMIE Trial. Ann. Surg. 275, 646–653 (2022).
pubmed: 34171870
doi: 10.1097/SLA.0000000000005023
Groth, S. S. et al. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J. Thorac. Cardiovasc. Surg. 139, 612–620 (2010).
pubmed: 19709685
doi: 10.1016/j.jtcvs.2009.07.017
Peyre, C. G. et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann. Surg. 248, 549–556 (2008).
pubmed: 18936567
doi: 10.1097/SLA.0b013e318188c474
Rizk, N. P. et al. Optimum lymphadenectomy for esophageal cancer. Ann. Surg. 251, 46–50 (2010).
pubmed: 20032718
doi: 10.1097/SLA.0b013e3181b2f6ee
Altorki, N. et al. Ten-year survival and recurrence patterns after three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann. Surg. https://doi.org/10.1097/SLA.0000000000005627 (2022).
doi: 10.1097/SLA.0000000000005627
pubmed: 35866662
Eyck, B. M. et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J. Clin. Oncol. 39, 1995–2004 (2021).
pubmed: 33891478
doi: 10.1200/JCO.20.03614
Kamel, M. K. et al. Extended lymphadenectomy improves survival after induction chemoradiation for esophageal cancer: a propensity matched analysis of the National Cancer Database. Ann. Surg. 277, e772–e776 (2023).
pubmed: 34475320
doi: 10.1097/SLA.0000000000005197
Visser, E., van Rossum, P. S. N., Ruurda, J. P. & van Hillegersberg, R. Impact of lymph node yield on overall survival in patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy for cancer: a population-based cohort study in the Netherlands. Ann. Surg. 266, 863–869 (2017).
pubmed: 28742691
doi: 10.1097/SLA.0000000000002389
Isono, K., Sato, H. & Nakayama, K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48, 411–420 (1991).
pubmed: 1745490
doi: 10.1159/000226971
Li, B. et al. Esophagectomy with three-field vs two-field lymphadenectomy for middle and lower thoracic esophageal cancer: long-term outcomes of a randomized clinical trial. J. Thorac. Oncol. 16, 310–317 (2021).
pubmed: 33307192
doi: 10.1016/j.jtho.2020.10.157
Lerut, T. et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann. Surg. 240, 962–972 (2004).
pubmed: 15570202
doi: 10.1097/01.sla.0000145925.70409.d7
pmcid: 1356512
Low, D. E. et al. Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS) society recommendations. World J. Surg. 434, 299–330 (2019).
doi: 10.1007/s00268-018-4786-4
Minnella, E. M. et al. Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: a randomized clinical trial. JAMA Surg. 153, 1081–1089 (2018).
pubmed: 30193337
doi: 10.1001/jamasurg.2018.1645
pmcid: 6583009
Allen, S. K. et al. Multimodal prehabilitation during neoadjuvant therapy prior to esophagogastric cancer resection: effect on cardiopulmonary exercise test performance, muscle mass and quality of life — a pilot randomized trial. Ann. Surg. Oncol. 29, 1839–1850 (2022).
pubmed: 34725764
doi: 10.1245/s10434-021-11002-0
Steffens, D. et al. Prehabilitation with preoperative exercise and education for patients undergoing major abdominal surgery: protocol for a multicenter randomised controlled trial (PRIORITY TRIAL). BMC Cancer 22, 443 (2022).
pubmed: 35459100
doi: 10.1186/s12885-022-09492-6
pmcid: 9026022
Mariette, C. et al. Health-related quality of life following hybrid minimally invasive versus open esophagectomy for patients with esophageal cancer, analysis of a multicenter, open-label, randomized phase III controlled trial: the MIRO trial. Ann. Surg. 271, 1023–1029 (2020).
pubmed: 31404005
doi: 10.1097/SLA.0000000000003559
Noordman, B. J. et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for esophageal cancer: a stepped-wedge cluster randomized trial. BMC Cancer https://doi.org/10.1186/s12885-018-4034-1 (2018).
doi: 10.1186/s12885-018-4034-1
pubmed: 29409469
pmcid: 5801846
Derogar, M. & Lagergren, P. Health-relted quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J. Clin. Oncol. 30, 413–418 (2012).
pubmed: 22215745
doi: 10.1200/JCO.2011.38.9791
Schreurs, L. M. et al. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomoography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal interobserver variability: PET/CT improves esophageal target definition. Dis. Esophagus 23, 493–501 (2010).
pubmed: 20113320
doi: 10.1111/j.1442-2050.2009.01044.x
Vosmik, M. et al. Technological advances in radiotherapy for esophageal cancer. World J. Gastroenterol. 16, 5555–5564 (2010).
pubmed: 21105188
doi: 10.3748/wjg.v16.i44.5555
pmcid: 2992673
Wang, J. et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int. J. Rad. Oncol. Biol. Phys. 86, 885–891 (2013).
doi: 10.1016/j.ijrobp.2013.04.006
Lin, S. H. et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J. Clin. Oncol. 38, 1569–1579 (2020).
pubmed: 32160096
doi: 10.1200/JCO.19.02503
pmcid: 7213588
Minsky, B. et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J. Clin. Oncol. 20, 1167–1174 (2002).
pubmed: 11870157
doi: 10.1200/JCO.2002.20.5.1167
Hulshof, M. C. C. et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study). J. Clin. Oncol. 39, 2816–2824 (2021).
pubmed: 34101496
doi: 10.1200/JCO.20.03697
Wang, X. et al. High versus standard radiation dose of definitive concurrent chemoradiotherapy for esophageal cancer: a systemic review and meta-analysis of randomized clinical trials. Radiother. Oncol. 180, 109463 (2023).
pubmed: 36642387
doi: 10.1016/j.radonc.2023.109463
Penniment, M. G. et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in adavced oesophageal cancer: a multicenter randomised controlled trial (TROG 03.01). Lancet Gastroenterol. Hepatol. 3, 114–124 (2017).
pubmed: 29248399
doi: 10.1016/S2468-1253(17)30363-1
Bass, G. A., Furlong, H., O’Sullivan, K. E., Hennessy, T. P. & Walsh, T. N. Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus. Eur. J. Cancer 50, 1065–1075 (2014).
pubmed: 24480403
doi: 10.1016/j.ejca.2013.12.022
Boonstra, J. J. et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 11, 181 (2011).
pubmed: 21595951
doi: 10.1186/1471-2407-11-181
pmcid: 3123658
Lv, J. et al. Long-term efficacy of periopeartive chemoradiotherapy on esophageal squamous cell carcinoma. World J. Gastroenterol. 16, 1649–1654 (2010).
pubmed: 20355244
doi: 10.3748/wjg.v16.i13.1649
pmcid: 2848374
Tepper, J. et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J. Clin. Oncol. 26, 1086–1092 (2008).
pubmed: 18309943
doi: 10.1200/JCO.2007.12.9593
Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20 (2006).
pubmed: 16822992
doi: 10.1056/NEJMoa055531
Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I. & Langley, R. E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J. Clin. Oncol. 27, 5062–5067 (2009).
pubmed: 19770374
doi: 10.1200/JCO.2009.22.2083
Zhao, Y. et al. Periopertive versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial. J. Thorac. Oncol. 10, 1349–1356 (2015).
pubmed: 26287319
doi: 10.1097/JTO.0000000000000612
Ando, N. et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann. Surg. Oncol. 19, 68–74 (2012).
pubmed: 21879261
doi: 10.1245/s10434-011-2049-9
Ychou, M. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 29, 1715–1721 (2011).
pubmed: 21444866
doi: 10.1200/JCO.2010.33.0597
Obermannova, R. et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 992–1004 (2022).
pubmed: 35914638
doi: 10.1016/j.annonc.2022.07.003
Klevebro, F. et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann. Oncol. 27, 660–667 (2016).
pubmed: 26782957
doi: 10.1093/annonc/mdw010
Stahl, M. et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinoma of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur. J. Cancer 81, 183–190 (2017).
pubmed: 28628843
doi: 10.1016/j.ejca.2017.04.027
Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).
pubmed: 30982686
doi: 10.1016/S0140-6736(18)32557-1
Bedenne, L. et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J. Clin. Oncol. 25, 1160–1168 (2007).
pubmed: 17401004
doi: 10.1200/JCO.2005.04.7118
Stahl, M. et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J. Clin. Oncol. 23, 2310–2317 (2005).
pubmed: 15800321
doi: 10.1200/JCO.2005.00.034
Swisher, S. G. et al. Final results of NRG Oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation. J. Thorac. Oncol. 12, 368–374 (2017).
pubmed: 27729298
doi: 10.1016/j.jtho.2016.10.002
van der Wilk, B. J. et al. Active surveillance versus immediate surgery in clinical complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study. Ann. Surg. https://doi.org/10.1097/SLA.0000000000003636 (2019).
doi: 10.1097/SLA.0000000000003636
Bolger, J. C., Donohoe, C. L., Lowery, M. & Reynolds, J. V. Advances in the curative management of oesophageal cancer. Br. J. Cancer 126, 706–717 (2022).
pubmed: 34675397
doi: 10.1038/s41416-021-01485-9
Cheedella, N. K. et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann. Oncol. 24, 1262–1266 (2013).
pubmed: 23247658
doi: 10.1093/annonc/mds617
Noordman, B. J. et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicenter, diagnostic cohort study. Lancet Oncol. 19, 965–974 (2018).
pubmed: 29861116
doi: 10.1016/S1470-2045(18)30201-8
Azad, T. D. et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 158, 494–505 (2020).
pubmed: 31711920
doi: 10.1053/j.gastro.2019.10.039
Wieder, H. A. et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J. Clin. Oncol. 22, 900–908 (2004).
pubmed: 14990646
doi: 10.1200/JCO.2004.07.122
Ott, K. et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J. Clin. Oncol. 24, 4692–4698 (2006).
pubmed: 16966684
doi: 10.1200/JCO.2006.06.7801
Lordick, F. et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8, 797–805 (2007).
pubmed: 17693134
doi: 10.1016/S1470-2045(07)70244-9
Goodman, K. A. et al. Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial. J. Clin. Oncol. 39, 2803–2815 (2021).
pubmed: 34077237
doi: 10.1200/JCO.20.03611
pmcid: 8407649
Cunningham, D. et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council STO3): primary analysis results of a multicenter open-label, randomised phase 2-3 trial. Lancet Oncol. 18, 357–370 (2017).
pubmed: 28163000
doi: 10.1016/S1470-2045(17)30043-8
pmcid: 5337626
Okines, A. F. C. et al. Biomarker analysis in oesophageal cancer: results from the REAL3 and TransMAGIC trials. Eur. J. Cancer 49, 2116–2125 (2013).
pubmed: 23481512
doi: 10.1016/j.ejca.2013.02.007
Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006).
pubmed: 16467544
doi: 10.1056/NEJMoa053422
Ruhstaller, T. et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann. Oncol. 29, 1386–1393 (2018).
pubmed: 29635438
doi: 10.1093/annonc/mdy105
Crosby, T. et al. SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. Br. J. Cancer 116, 709–716 (2017).
pubmed: 28196063
doi: 10.1038/bjc.2017.21
pmcid: 5355926
Suntharalingam, M. et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer. The NRG Oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 3, 1520–1528 (2017).
pubmed: 28687830
doi: 10.1001/jamaoncol.2017.1598
pmcid: 5710193
Safran, H. P. et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicenter, randomised, phase 3 trial. Lancet Oncol. 23, 259–269 (2022).
pubmed: 35038433
doi: 10.1016/S1470-2045(21)00718-X
pmcid: 8903071
Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
pubmed: 20728210
doi: 10.1016/S0140-6736(10)61121-X
Lynce, F. & Swain, S. M. Pertuzumab for the treatment of breast cancer. Cancer Invest. 32, 430–438 (2014).
pubmed: 24921704
doi: 10.3109/07357907.2014.922570
Hofheinz, R. D. et al. FLOT versus FLOT/trastuzumab/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J. Clin. Oncol. 40, 3750–3761 (2022).
pubmed: 35709415
doi: 10.1200/JCO.22.00380
Shah, M. A. Update on metastatic gastric and esophageal cancers. J. Clin. Oncol. 33, 1760–1769 (2015).
pubmed: 25918288
doi: 10.1200/JCO.2014.60.1799
Al-Batran, S. E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26, 1435–1442 (2008).
pubmed: 18349393
doi: 10.1200/JCO.2007.13.9378
Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).
pubmed: 18172173
doi: 10.1056/NEJMoa073149
Kang, Y. K. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann. Oncol. 20, 666–673 (2009).
pubmed: 19153121
doi: 10.1093/annonc/mdn717
Van Cutsem, E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24, 4991–4997 (2006).
pubmed: 17075117
doi: 10.1200/JCO.2006.06.8429
Shah, M. A. et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J. Clin. Oncol. 33, 3874–3879 (2015).
pubmed: 26438119
doi: 10.1200/JCO.2015.60.7465
Lorenzen, S. et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann. Oncol. 18, 1673–1679 (2007).
pubmed: 17660494
doi: 10.1093/annonc/mdm269
Al-Batran, S. E. et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol. 19, 1882–1887 (2008).
pubmed: 18669868
doi: 10.1093/annonc/mdn403
Lu, B. et al. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol. Res. 50, 269–275 (2011).
pubmed: 21717068
doi: 10.1007/s12026-011-8227-9
Ohigashi, Y. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11, 2947–2953 (2005).
pubmed: 15837746
doi: 10.1158/1078-0432.CCR-04-1469
Shah, M. A. et al. T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol. https://doi.org/10.2217/fon-2021-1134 (2022).
doi: 10.2217/fon-2021-1134
pubmed: 36377973
Kato, K. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (Attraction-3): a multicenter, randomised, open label phase 3 trial. Lancet Oncol. 20, 1506–1517 (2019).
pubmed: 31582355
doi: 10.1016/S1470-2045(19)30626-6
Huang, J. et al. Camrelizumab versus investigator’s choice of chemotherapy as 2nd line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicenter, randomised, open-label, phase 3 study. Lancet Oncol. 21, 832–842 (2020).
pubmed: 32416073
doi: 10.1016/S1470-2045(20)30110-8
Shen, L. et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (Rationale-302): a randomized phase III study. J. Clin. Oncol. 40, 3065–3076 (2022).
pubmed: 35442766
doi: 10.1200/JCO.21.01926
pmcid: 9462531
Bang, Y. J. et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-esophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29, 2052–2060 (2018).
pubmed: 30052729
doi: 10.1093/annonc/mdy264
pmcid: 6225815
Luo, H. et al. Effect of camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st Randomized Clinical Trial. JAMA 326, 916–925 (2021).
pubmed: 34519801
doi: 10.1001/jama.2021.12836
pmcid: 8441593
Lu, Z. et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinioma (ORIENT-15): multicenter, randomised, double blind, phase 3 trial. BMJ 377, e068714 (2022).
pubmed: 35440464
doi: 10.1136/bmj-2021-068714
pmcid: 9016493
Wang, Z. X. et al. Toripalimab plus chemotherapy in treatment-naive advanced esophageal squamous cell carcinoma (Jupiter-06): a multi-center phase 3 trial. Cancer Cell 40, 277–288 (2022).
pubmed: 35245446
doi: 10.1016/j.ccell.2022.02.007
Chaganty, B. K. R. et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNy secretion. Cancer Lett. 430, 47–56 (2018).
pubmed: 29746929
doi: 10.1016/j.canlet.2018.05.009
pmcid: 6004098
Varadan, V. et al. Immune signatures following single dose trastuzumab predict pathologic response to preoperative trastuzumab and chemotherapy in HER2-positive early breast cancer. Clin. Cancer Res. 22, 3249–3259 (2016).
pubmed: 26842237
doi: 10.1158/1078-0432.CCR-15-2021
pmcid: 5439498
Song, Y. et al. First-line serplulimab or placebo plus chemotherapy in PD-L1 positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat. Med. 29, 473–482 (2023).
pubmed: 36732627
doi: 10.1038/s41591-022-02179-2
pmcid: 9941045